The WACC of Mochida Pharmaceutical Co Ltd (4534.T) is 6.0%.
Range | Selected | |
Cost of equity | 5.2% - 6.8% | 6% |
Tax rate | 27.1% - 27.7% | 27.4% |
Cost of debt | 4.0% - 4.5% | 4.25% |
WACC | 5.1% - 6.8% | 6.0% |
Category | Low | High |
Long-term bond rate | 1.4% | 1.9% |
Equity market risk premium | 6.1% | 7.1% |
Adjusted beta | 0.61 | 0.63 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 5.2% | 6.8% |
Tax rate | 27.1% | 27.7% |
Debt/Equity ratio | 0 | 0 |
Cost of debt | 4.0% | 4.5% |
After-tax WACC | 5.1% | 6.8% |
Selected WACC | 6.0% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
4534.T | Mochida Pharmaceutical Co Ltd | 1.1 | 0.67 | 0.37 |
4521.T | Kaken Pharmaceutical Co Ltd | 0.02 | 0.27 | 0.27 |
4538.T | Fuso Pharmaceutical Industries Ltd | 1.05 | 0.76 | 0.43 |
4540.T | Tsumura & Co | 0.27 | 0.55 | 0.46 |
4547.T | Kissei Pharmaceutical Co Ltd | 0.01 | 0.43 | 0.43 |
4551.T | Torii Pharmaceutical Co Ltd | 0 | 0.81 | 0.81 |
4553.T | Towa Pharmaceutical Co Ltd | 1.47 | 0.85 | 0.41 |
4559.T | Zeria Pharmaceutical Co Ltd | 0.36 | 0.42 | 0.33 |
4569.T | Kyorin Holdings Inc | 0.29 | 0.55 | 0.45 |
4577.T | Daito Pharmaceutical Co Ltd | 0.27 | 0.36 | 0.3 |
Low | High | |
Unlevered beta | 0.4 | 0.43 |
Relevered beta | 0.42 | 0.45 |
Adjusted relevered beta | 0.61 | 0.63 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 4534.T:
cost_of_equity (6.00%) = risk_free_rate (1.65%) + equity_risk_premium (6.60%) * adjusted_beta (0.61) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.